Zevra’s Chief Medical Officer to Step Down for Personal Reasons as Part of Planned Transition

Rhea-AI Summary

Zevra Therapeutics (NasdaqGS: ZVRA) announced that Chief Medical Officer Adrian Quartel will step down for personal reasons effective July 3, 2026. He will remain a consultant through December 31, 2026 while Zevra searches for a new CMO and manages the transition.

Zevra reports it remains on track with key regulatory milestones, including an EMA review of its arimoclomol MAA for Niemann-Pick disease type C and an ongoing Phase 3 celiprolol trial in Vascular Ehlers-Danlos Syndrome, with further FDA discussions planned in the second half of 2026.

Positive

• Departing CMO to provide consulting support through December 31, 2026
• Company states it remains on track with multiple regulatory milestones
• Arimoclomol MAA for Niemann-Pick disease type C under EMA review
• Ongoing Phase 3 celiprolol trial for Vascular Ehlers-Danlos Syndrome
• Planned FDA dialogue in H2 2026 on celiprolol development program

Negative

• Chief Medical Officer stepping down effective July 3, 2026
• Leadership transition during ongoing late-stage and regulatory programs

News Market Reaction – ZVRA

-3.93%

16 alerts

-3.93% Session close to close

+8.6% Peak Tracked

-2.0% Trough Tracked

$811.95M Market Cap

0.2x Rel. Volume

In the Jun 11 session, ZVRA declined 3.93%, reflecting a moderate negative market reaction. Argus tracked a peak move of +8.6% during that session. Argus tracked a trough of -2.0% from its starting point during tracking. Our momentum scanner triggered 16 alerts that day, indicating notable trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details a planned CMO transition effective July 3, 2026, with continued consulting...

Analysis

This announcement details a planned CMO transition effective July 3, 2026, with continued consulting support through December 31, 2026. It highlights that Zevra’s strategic programs remain intact, including the EMA review of arimoclomol for NPC and a Phase 3 celiprolol trial for VEDS, alongside planned FDA discussions in the second half of 2026. Investors may watch for progress on these milestones and the appointment of a new CMO as indicators of ongoing execution strength.

Key Figures

CMO end date: July 3, 2026 Consulting support end: December 31, 2026 Phase: Phase 3 +5 more

8 metrics

CMO end date July 3, 2026 Effective date for Chief Medical Officer stepping down

Consulting support end December 31, 2026 Date through which Dr. Quartel will consult for Zevra

Phase Phase 3 Ongoing celiprolol trial for Vascular Ehlers-Danlos Syndrome (VEDS)

MAA status Under review Arimoclomol MAA for Niemann-Pick disease type C at EMA

Timeline Second half of 2026 Planned further FDA dialogue on celiprolol development program

Current price $13.50 Price before news; about 5.4% below 52-week high

Price vs 52-week low 88.55% Gain from 52-week low of $7.16 to current price

Market cap $807,512,047 Equity value prior to this leadership transition news

Historical Context

5 past events · Latest: Jun 08 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 08	IP / exclusivity	Positive	+12.5%	Orange Book listing for MIPLYFFA patent aimed at extending NPC exclusivity.
May 29	HR / compensation	Neutral	-0.9%	Nasdaq Rule 5635(c)(4) inducement option grants for new employees.
May 12	Investor conference	Positive	+2.3%	Announcement of participation in H.C. Wainwright BioConnect Investor Conference.
May 06	Earnings & update	Positive	-2.2%	Q1 2026 results with net revenue growth and SDX portfolio sale details.
Apr 22	Earnings call notice	Neutral	+1.9%	Scheduling of Q1 2026 financial results release and conference call.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news has often produced modest moves, with stronger reactions around IP and earnings events. Positive IP protection news drew a larger gain, while solid earnings coincided with a small decline, indicating mixed alignment between fundamentals and short-term price moves.

Recent Company History

Over the past months, ZVRA has highlighted strengthening of MIPLYFFA’s IP position (Orange Book listing news on Jun 8, 2026), routine corporate actions like inducement grants, and active investor engagement via conferences. Financial updates on May 6, 2026 showed a Q1 2026 turnaround with higher net revenue and a corporate update, following an earlier call announcement on Apr 22, 2026. Today’s CMO transition sits against this backdrop of expanding commercialization, regulatory progress, and maturing corporate infrastructure.

Key Terms

marketing authorisation application, maa, niemann-pick disease type c, european medicines agency, +4 more

8 terms

marketing authorisation application regulatory

"Zevra remains on track with multiple regulatory milestones, including its Marketing Authorisation Application (MAA)..."

A marketing authorisation application is the formal package a drug or medical-device maker submits to a health regulator to get permission to sell a product. Think of it as an application for a sales license: regulators review safety, effectiveness and manufacturing quality before granting permission. Investors watch these submissions because approval unlocks revenue and reduces development risk, while rejection or delays can materially affect a company’s value and timeline.

maa regulatory

"including its Marketing Authorisation Application (MAA) for the evaluation of arimoclomol..."

MAA stands for Marketing Authorization Application, the formal request a drug developer files with regulators (commonly in the European Union) asking for permission to sell a medicine. Think of it like applying for a driver’s license for a product: approval means the company can market and earn revenue from the drug, while rejection or delays affect expected sales, timelines and the company’s valuation—so investors track MAAs as key risk/reward milestones.

niemann-pick disease type c medical

"for the treatment of Niemann-Pick disease type C (NPC), which is currently under review..."

A rare inherited disorder in which cells cannot move cholesterol and other fats properly, causing them to build up like a clogged waste line and leading to progressive neurological problems, liver dysfunction, and variable symptoms that can appear from infancy to adulthood. It matters to investors because effective treatments are limited, so drug candidates can attract strong regulatory incentives, premium pricing and focused patient populations, but clinical development is small, risky and uncertain.

european medicines agency regulatory

"currently under review by the European Medicines Agency."

The European Medicines Agency is the central drug regulator that evaluates and authorizes medicines for use across the European Union and related countries, similar to a referee or safety inspector who checks that a medicine is safe and effective before it can be sold. Its decisions matter to investors because approvals, rejections, or safety warnings directly affect a drug maker’s ability to sell products, generate revenue, and face legal or reputational risks, which in turn influence stock value.

phase 3 medical

"The Company is also conducting a Phase 3 trial of celiprolol for Vascular Ehlers-Danlos Syndrome..."

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

vascular ehlers-danlos syndrome medical

"Phase 3 trial of celiprolol for Vascular Ehlers-Danlos Syndrome (VEDS)..."

A rare inherited disorder that weakens the body’s connective “scaffolding,” making arteries and organs more prone to tears or ruptures; think of it like faulty plumbing or wiring inside blood vessels that can burst unexpectedly. It matters to investors because it defines a specific patient population, creates urgent medical need for treatments or diagnostics, and influences the risk/reward for drug development, clinical trial design, regulatory approval, and healthcare costs.

u.s. food and drug administration regulatory

"preparing for further dialogue in the second half of 2026 with the U.S. Food and Drug Administration (FDA)..."

The U.S. Food and Drug Administration is the federal agency that evaluates and enforces safety, effectiveness and labeling standards for medicines, medical devices, vaccines, food and related products before they reach consumers. For investors it matters because FDA approvals, warnings or recalls determine whether a product can be sold, how quickly it reaches the market and how costly compliance will be—changes that directly affect a company’s revenue, costs and stock value.

fda regulatory

"with the U.S. Food and Drug Administration (FDA) to potentially accelerate the development program."

The FDA is the U.S. federal agency that evaluates and approves medical drugs, devices, biological therapies and certain foods; think of it as the gatekeeper that decides whether a medical product is safe and effective for patients. For investors, FDA decisions determine whether a company can sell a product, affect expected revenue and introduce regulatory risk, so approvals, rejections or safety warnings can quickly move a company's valuation and stock price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON, June 11, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, announced today that its Chief Medical Officer (“CMO”) Adrian Quartel, M.D., FFPM, will be stepping down from his position due to personal reasons, effective July 3, 2026. Dr. Quartel will continue to support Zevra in a consulting capacity through December 31, 2026, while the Company conducts a search for its next CMO and ensures a seamless transition.

“On behalf of everyone at Zevra, we are grateful for the role Adrian played in advancing our mission and positioning us for success. Over the past several years, he has been a trusted partner, contributing to the FDA approval and commercial launch of MIPLYFFA, advancing celiprolol, and supporting the arimoclomol MAA submission,” said Neil F. McFarlane, Zevra’s Chief Executive Officer and President. “Adrian’s contributions helped build a strong foundation for our next phase of growth, and we are well positioned to execute on our upcoming milestones and pipeline priorities.”

Zevra remains on track with multiple regulatory milestones, including its Marketing Authorisation Application (MAA) for the evaluation of arimoclomol for the treatment of Niemann-Pick disease type C (NPC), which is currently under review by the European Medicines Agency. The Company is also conducting a Phase 3 trial of celiprolol for Vascular Ehlers-Danlos Syndrome (VEDS) and is preparing for further dialogue in the second half of 2026 with the U.S. Food and Drug Administration (FDA) to potentially accelerate the development program. 

"It has been a true privilege to be part of the Zevra team during such a pivotal time in the Company’s history,” said Dr. Quartel. “Working alongside a talented and dedicated team committed to advancing exceptional therapeutics for patients with rare diseases has been both professionally rewarding and personally meaningful. I am grateful for the opportunity to have contributed to Zevra’s growth and evolution, and I leave with tremendous confidence in the Company’s future.”

About Zevra Therapeutics, Inc.

Zevra Therapeutics, Inc. is a commercial-stage company with a late-stage pipeline committed to redefining what is possible in bringing life-changing therapies to people living with rare diseases. The Company is focused on broadening access through geographic expansion opportunities, progressing its pipeline toward key milestones, and delivering meaningful therapeutics. The commercialization of its lead product, marketed in the U.S. for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a strong corporate foundation and validates its ability to advance therapies from development to market. Zevra's vision is realized through disciplined execution of its strategic plan and core values — patient centricity, integrity, accountability, innovation, and courage — which guide its efforts to deliver long-term value.

For more information, please visit www.zevra.com or follow us on X and LinkedIn.

Cautionary Note Concerning Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on information currently available to Zevra and its current plans or expectations. They are subject to several known and unknown uncertainties, risks, and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the “Risk Factors” section of Zevra’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission on March 9, 2026 and Zevra’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, filed on May 6, 2026, and Zevra's other filings with the Securities and Exchange Commission. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Although we believe the expectations reflected in such forward-looking statements are reasonable, we cannot assure that such expectations will prove correct. These forward-looking statements should not be relied upon as representing our views as of any date after the date of this press release.

Investor Contact

Nichol Ochsner 
+1 (732) 754-2545 
nochsner@zevra.com

Media Contact

Julie Downs
+1 (508) 246-3230 
jdowns@zevra.com

FAQ

Why is Zevra (ZVRA) Chief Medical Officer Adrian Quartel stepping down in July 2026?

Adrian Quartel is stepping down as Zevra’s Chief Medical Officer for personal reasons, effective July 3, 2026. According to Zevra, he will continue supporting the company in a consulting role through December 31, 2026 to help ensure a smooth leadership transition.

When does the Zevra (ZVRA) CMO transition take effect and how long will consulting support last?

The CMO transition at Zevra takes effect on July 3, 2026, with consulting support through year-end. According to Zevra, Adrian Quartel will remain engaged until December 31, 2026 while the company conducts its search for a new Chief Medical Officer.

What regulatory milestones did Zevra (ZVRA) highlight in its June 11, 2026 announcement?

Zevra highlighted that it remains on track with multiple regulatory milestones across its rare disease portfolio. According to Zevra, these include EMA review of arimoclomol’s MAA for Niemann-Pick disease type C and ongoing work to advance a Phase 3 celiprolol program.

What is the status of Zevra (ZVRA) arimoclomol MAA for Niemann-Pick disease type C?

Zevra’s Marketing Authorisation Application for arimoclomol in Niemann-Pick disease type C is under EMA review. According to Zevra, this MAA covers evaluation of arimoclomol as a potential treatment option for NPC, reflecting a key regulatory milestone in its rare disease pipeline.

What did Zevra (ZVRA) report about its Phase 3 celiprolol trial for VEDS?

Zevra reported that it is conducting a Phase 3 trial of celiprolol for Vascular Ehlers-Danlos Syndrome (VEDS). According to Zevra, the company is preparing for further dialogue with the U.S. FDA in the second half of 2026 to potentially accelerate this development program.

How might the Zevra (ZVRA) CMO change affect its pipeline and regulatory plans?

Zevra stated it remains well positioned to execute upcoming milestones despite the CMO change. According to Zevra, Adrian Quartel will consult through December 31, 2026 while the company continues EMA review for arimoclomol and advances its Phase 3 celiprolol trial and FDA discussions.

What experience did Zevra (ZVRA) attribute to outgoing CMO Adrian Quartel in its June 2026 update?

Zevra credited Adrian Quartel with contributing to the FDA approval and launch of MIPLYFFA and key pipeline advances. According to Zevra, he supported celiprolol’s progress and the arimoclomol MAA submission, helping build the company’s rare disease development and commercialization foundation.